医药业ESG披露率五连增 推进“三废”治理向绿而行

Core Viewpoint - The pharmaceutical industry is increasingly integrating ESG (Environmental, Social, and Governance) principles into its operations, with a notable rise in ESG report disclosures among listed companies, reflecting a commitment to high-quality development and sustainable practices [1][2]. Group 1: ESG Report Disclosure - In 2024, 495 pharmaceutical and biotechnology companies disclosed ESG reports, achieving a disclosure rate of 43.26% [1]. - The ESG report disclosure rates from 2019 to 2023 were 23.66%, 24.11%, 29.67%, 32.91%, and 39.19%, indicating a consistent upward trend [1]. - Companies in economically developed regions, such as Beijing, Shanghai, and Guangdong, generally outperform those in less developed areas like Guangxi and Shanxi in ESG practices [1]. Group 2: ESG Ratings Distribution - Among the companies that disclosed ESG reports in 2024, 13 received an AAA rating (2.63%), and 63 received an AA rating (12.73%) [2]. - The majority of ESG ratings are concentrated in the A, BBB, and BB categories, with 98 companies rated A (19.8%), 85 rated BBB (17.17%), and 128 rated BB (25.86%) [2]. - The median score for the pharmaceutical and biotechnology industry is 65.57, with the highest score being 84.06 from Darentang and the lowest being 50.69 from Digital Human [2]. Group 3: ESG Practices by Sub-Sectors - The chemical pharmaceutical sector had 157 companies disclose ESG reports, with ratings distributed as follows: 1 AAA, 14 AA, 37 A, 31 BBB, 49 BB, 24 B, and 1 CCC [3]. - The traditional Chinese medicine sector had 69 companies disclose ESG reports, with 6 rated AAA, 11 AA, and 8 A [3]. - The medical device sector had 131 companies disclose ESG reports, with 2 rated AAA, 15 AA, and 18 A [3]. Group 4: Environmental Management Practices - By 2025, the pharmaceutical industry is shifting from end-of-pipe management to comprehensive control of environmental practices, with leading companies establishing systematic management systems for waste treatment [4]. - Companies like Pizaihuang and Baiyi Shenzhou are implementing innovative practices for wastewater treatment and solid waste management, showcasing a commitment to environmental sustainability [4]. - R&D innovation is a core focus, with companies integrating ESG principles into their research processes, exemplified by Wantai Biologics' development of a nine-valent HPV vaccine [4]. Group 5: Corporate Initiatives and Investments - Yunnan Baiyao is leveraging AI in drug development and has established a business matrix across various health fields [5]. - Companies prioritize product quality and safety, with Zhifei Biological implementing animal welfare and ethical standards in its operations [5]. - Darentang has disclosed ESG reports for 18 consecutive years, achieving energy savings of 101.95 tons of standard coal through equipment upgrades [6]. Group 6: Green Transformation and Community Engagement - Yiyue Medical is accelerating its green transformation with an investment of 4.82 million in environmental initiatives, achieving a 100% compliance rate in waste emissions [7]. - The company has integrated green development principles into its operations and achieved ISO 14001 certification as a "Green Factory" [7]. - Yiyue Medical also engages in community support, contributing 1.47 million to various public welfare projects [8].